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Efficacy of nucleoside analogues for hepatitis B virus-related 
liver failure: A network meta-analysis
The purpose of this study was to compare the efficacy of 
nucleoside analogues (NAs) in the treatment of HBV-related 
liver failure. The data of patients with HBV-related liver 
failure treated with nucleoside analogues were used to con-
duct a network meta-analysis. A total of 1660 patients from 
12 articles about the efficacy of lamivudine, entecavir, telbi-
vudine and tenofovir for HBV-related liver failure treat-
ment were recruited in the study. The highest two- and 
three-month survival rate was recorded for patients using 
tenofovir. The end-stage liver disease (MELD) score and 
mortality in patients undergoing tenofovir treatment were 
the lowest. Patients treated with telbivudine had the high-
est one-month survival rate. Patients receiving enticavir 
therapy showed the lowest HBV DNA level. Our results 
indicate that tenofovir may be the best therapy for the treat-
ment of HBV-related liver failure compared to other nucleo-
side analogues (including lamivudine, entecavir and telbi-
vudine) and non-NAs treatment.
Keywords: liver failure, hepatitis B virus, nucleoside ana-
logue, tenofovir, network meta-analysis
Hepatitis B virus (HBV) infection, the leading cause of liver failure, is a global health 
problem with more than 400 million people infected worldwide up to now (1). HBV-related 
liver diseases cause over 1 million deaths every year (2). Active HBV infection can be indi-
cated by hepatitis B surface antigen and HBV DNA in serum (3). The pathogenesis of liver 
failure caused by HBV infection is as follows. HBV replication leads to a primary injury of 
liver cells and the host’s immune cells such as cytotoxic T lymphocytes, and HBV replica-
tion causes a secondary lesion to the HBV-infected hepatocytes during viral clearance (4). 
Following this, patients may suffer from another two attacks of ischemic-hypoxic injury 
and endotoxemia (5). 
There is no standard therapy for liver failure. Although liver transplantation is con-
sidered a life-saving treatment, its clinical use is hindered by the difficulty of finding suit-
able donors (6). Although an artificial and bioartificial liver support system is available for 
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years, efficacy of nucleoside analogues, such as lamivudine, entecavir, telbivudine and 
tenofovir, for HBV-related liver failure has been reported. Nucleoside analogues are anti-
viral drugs that prevent the progression of liver failure by reducing HBV DNA replication 
through suppression of HBV-polymerase activity (8). There have been meta-analyses of the 
effects of nucleoside analogues for HBV-related liver failure treatment (9–11). Some of them 
compare the outcomes of two kinds of nucleoside analogues while the others analyze the 
efficacy of nucleoside analogue treatment in comparison with the non-nucleoside ana-
logue (non-NA) treatment (10, 11). However, no conclusion on which nucleoside analogue 
is the most satisfactory drug for the treatment of HBV-related liver failure has not been 
reached yet. Therefore, a comprehensive comparison of lamivudine, entecavir, telbivudine 
and tenofovir efficacy for the HBV-related liver failure treatment is essential.
To identify the optimal therapy, a Bayesian network meta-analysis was conducted. Ar-
ticles about the efficacy of lamivudine, entecavir, telbivudine and tenofovir for the HBV-re-
lated liver failure treatment were reviewed to evaluate the outcomes, including one-month 
to three-month survival rates, HBV DNA (log IU mL–1 indicates virological characteristics), 
model of the end-stage liver disease (MELD) score (consists of three objective parameters, 
TBIL, Cr and INR, which indicate the severity of the liver condition) and mortality.
DATA SOURCES
Literature search strategy
Network meta-analysis was performed following the guidelines of PRISMA-NMA 
(12). Relevant studies were obtained by searching electronic databases up to December 
2016, including Pubmed and Embase. Keywords used for literature search were as follows: 
(hepatitis B or HBV) and (hepatic failure or liver failure or hepatargia) and (nucleoside 
analog* or nucleotide analog* or nucleoside analogue or lamivudine or LAM or entecavir 
or ETV or telbivudine or LdT or tenofovir disoproxil fumarate or TDF or adefovir). Lan-
guage was restricted to English. In addition, the lists of retrieved articles were reviewed 
to identify additional literature.
Inclusion and exclusion criteria
Studies were included into this article if they met the following criteria: patients with 
HBV-related liver failure (P), treatment of HBV-related liver failure using a nucleoside 
analogue (I), studies including a comparison of several nucleoside analogues (C), out-
comes including at least one of the following indicators: mortality, survival, HBV DNA or 
MELD score (O). Besides, repetitive publications, studies without sufficient original data 
for statistical analysis, studies with sample size less than five, reviews, reports, comments 
and letters were excluded.
Data extraction and quality assessment
Data extraction was performed by two investigators independently. Data extracted 
from each retrieved article were as follows: the first author’s name, publication year, loca-
tion, study period, study type, follow-up time, number of subjects, demographic data charac-
teristics including gender, age, etc., and outcomes of indicators. Quality assessment of 
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randomized controlled trials (RCTs) was conducted using the Cochrane risk of bias tool 
recommended in the Cochrane handbook. Methodological quality of cohort studies was 
analyzed according to the Newcastle-Ottawa Scale (NOS, G. A. Wells et al., University of 
Ottawa, Ontario, Canada). Any discrepancy during data extraction and quality assessment 
was solved through discussion with a third person.
STATISTICAL ANALYSIS
ADDIS software (1.16.5) (H. Hillege et al., University of Groningen, Research Institute 
SOM - Systems, Organisations and Management, 2012) is a non-programming software used 
for prior assessment and implementation based on the Bayesian framework using the Mar-
kov chain Monte Carlo (MCMC) (13). The network meta-analysis was performed by ADDIS 
software. Parameter settings of ADDIS software were as follows: the number of chains: 4, 
tuning iterations: 20000, simulation iterations: 50000, thinning interval: 10, inference sam-
ples: 10000, variance scaling factor: 2.5, and odds risk (OR) with 95 % confidence interval (CI) 
or mean difference (MD) with 95 % CI were used to estimate the data. In this study, all 
models were random effect models. Node-splitting analysis was used to evaluate inconsis-
tency. When p-value was > 0.05, a consistency model was used; otherwise, an inconsistency 
model was used. Convergences of models were estimated by the Brooks-Gelman-Rubin 
method via checking the potential scale reduction factor (PSRF) (14). The PSRF close to 1 
indicates good convergence of the models and, in general, PSRF less than 1.2 is acceptable.
RESEARCH OUTCOMES
Characteristics of available studies
The flow chart of study selection and literature search is shown in Fig. 1. After compre-
hensive search of the Pubmed and Embase databases, a total of 821 studies were identified. 
Fig. 1. Flow chart of study selection and literature search.
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After a series of selections and searches, 12 articles were included in our meta-analysis 
(15–26). The total number of hepatic failure patients was 1660, among which 563 patients 
were treated with lamivudine, 520 patients were treated with enticavir, 105 patients were 
treated with telbivudine, 14 patients were treated with tenofovir and 458 patients were treat-
ed with non-nucleoside analogues (non-NAs). The main characteristics of eligible studies are 
given in Table I. Quality assessment revealed that the quality of each study was high: NOS 
scores of the cohort study ranged from 6 to 9 and most of the categories were of low risk in 
the RCT study.
Network meta-analyses of survival rates
One-month survival rate, two-month survival rate and three-month survival rate 
were analyzed using ADDIS software. Inconsistency was estimated by the node-splitting 
analysis; p > 0.05 indicated consistency (Table II). The PSRFs ranged from 1.00 to 1.02, sug-
gesting that convergence of the models was complete, the effects of iteration were very 
good and the results were stable. Therefore, consistency models were chosen. As shown 
in Table III and Fig. 2a, the one-month survival rate in the telbivudine group patients was 
Table II. Node-splitting analyses of outcomes in patients undergoing different treatments [log OR (95 % CI)]
Name Direct effect Indirect effect Overall p-value
A: One-month survival rate
Enticavir, lamivudine –0.59 (–2.24, 1.03) 2.46 (–0.82, 6.04) –0.14 (–1.92, 1.59) 0.08
Enticavir, non-NAs –0.65 (–2.13, 0.90) –3.72 (–7.38, –0.58) –1.12 (–2.88, 0.58) 0.07
Lamivudine, non-NAs –1.41 (–3.96, 1.11) –0.16 (–3.35, 3.15) –0.95 (–2.95, 0.98) 0.48
B: Two-month survival rate
Enticavir, Lamivudine –0.28 (–1.53, 0.97)  0.01 (–2.09, 1.99) –0.20 (–1.30, 0.89) 0.77
Enticavir, non-NAs –0.35 (–1.83, 1.04) –1.52 (–3.63, 0.73) –0.68 (–1.93, 0.59) 0.31
Enticavir, telbivudine –0.20 (–2.15, 1.91)  1.02 (–1.66, 3.84) –0.08 (–1.53, 1.53) 0.43
Lamivudine, non-NAs –0.67 (–2.17, 0.92) –0.09 (–2.51, 2.52) –0.48 (–1.69, 0.79) 0.62
C: Three-month survival rate
Enticavir, lamivudine 0.19 (–0.30, 0.64)  0.53 (–0.31, 1.43) 0.24 (–0.17, 0.69) 0.44
Enticavir, non-NAs –0.65 (–1.23, –0.09) –1.03 (–1.83, –0.31) –0.76 (–1.26, –0.27) 0.37
Lamivudine, non-NAs –1.06 (–1.59, –0.57) –0.57 (–1.68, 0.57) –1.00 (–1.48, –0.59) 0.41
D: HBV DNA
Lamivudine, non-NAs 1.13 (–0.40, 2.48)  5.81 (3.69, 7.90) 2.29 (–0.04, 4.54) 0.01
E: MELD score
Enticavir, lamivudine 0.18 (–2.63, 2.94) 3.42 (–3.40, 10.32) 0.70 (–1.82, 3.39) 0.29
Enticavir, non-NAs  5.20 (1.09, 9.12)  1.95 (–3.93, 7.89)  4.08 (0.77, 7.52) 0.28
Lamivudine, non-NAs 1.73 (–3.83, 7.23)  5.05 (0.13, 9.53) 3.37 (–0.23, 7.07) 0.28
F: Mortality
Enticavir, lamivudine 0.03 (–0.71, 0.78) –0.89 (–2.23, 0.44) –0.23 (–0.93, 0.51) 0.21
Enticavir, non-NAs 0.22 (–0.60, 1.07)  1.69 (0.50, 3.02) 0.63 (–0.16, 1.47) 0.04
Enticavir, telbivudine 0.04 (–1.82, 1.90) –1.39 (–3.94, 1.04) –0.33 (–1.76, 1.06) 0.33
Lamivudine, non-NAs  1.25 (0.53, 1.99) –0.42 (–1.69, 0.71)  0.86 (0.08, 1.67) 0.01
CI – confidence interval, non-NAs – non-nucleoside analogues, OR – odds risk
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Table III. Network meta-analyzes of outcomes in patients undergoing different treatments
A: One-month survival rate                            OR (95 % CI)        
Enticavir 0.87 (0.15, 4.90) 0.79 (0.01, 43.92) 0.33 (0.06, 1.78) 1.09 (0.05, 22.52)
1.15 (0.20, 6.82) Lamivudine 0.94 (0.01, 56.66) 0.39 (0.05, 2.68) 1.25 (0.07, 27.34)
1.27 (0.02, 74.57) 1.07 (0.02, 68.35) Tenofovir 0.42 (0.01, 15.52) 1.38 (0.01, 204.33)
3.05 (0.56, 17.77) 2.59 (0.37, 19.16) 2.36 (0.06, 93.61) non-NAs 3.32 (0.13, 99.93)
0.92 (0.04, 18.52) 0.80 (0.04, 14.68) 0.72 (0.00, 102.99) 0.30 (0.01, 7.68) Telbivudine
B: Two-month survival rate                            OR (95 % CI)          
Enticavir 0.81 (0.27, 2.43) 6.18 (0.35, 163.02) 0.51 (0.15, 1.81) 0.92 (0.22, 4.63)
1.23 (0.41, 3.68) Lamivudine 7.77 (0.43, 188.47) 0.62 (0.18, 2.19) 1.13 (0.30, 5.41)
0.16 (0.01, 2.83) 0.13 (0.01, 2.32) Tenofovir 0.08 (0.00, 1.14) 0.15 (0.00, 3.88)
1.97 (0.55, 6.89) 1.61 (0.46, 5.41) 12.37 (0.88, 248.54) non-NAs 1.84 (0.32, 11.98)
1.09 (0.22, 4.64) 0.89 (0.18, 3.29) 6.73 (0.26, 202.01) 0.54 (0.08, 3.08) Telbivudine
C: Three-month survival rate                            OR (95 % CI)
Enticavir 1.27 (0.84, 2.00) 3.94 (0.57, 33.21) 0.47 (0.28, 0.77) 0.93 (0.42, 2.02)
0.79 (0.50, 1.19) Lamivudine 3.09 (0.46, 25.94) 0.37 (0.23, 0.55) 0.72 (0.34, 1.58)
0.25 (0.03, 1.75) 0.32 (0.04, 2.18) Tenofovir 0.12 (0.01, 0.76) 0.24 (0.03, 1.97)
2.15 (1.31, 3.52) 2.72 (1.81, 4.39) 8.30 (1.31, 69.38) non-NAs 1.98 (0.87, 4.71)
1.07 (0.50, 2.36) 1.38 (0.63, 2.98) 4.18 (0.51, 39.41) 0.51 (0.21, 1.15) Telbivudine
D: HBV DNA                                  MD (95 % CI)
Enticavir 0.33 (–1.25, 1.91) 2.66 (0.16, 5.19) 0.25 (–4.08, 4.73)
–0.33 (–1.91, 1.25) Lamivudine 2.21 (–0.81, 5.20) –0.05 (–4.18, 4.05)
–2.66 (–5.19, –0.16) –2.21 (–5.20, 0.81) non-NAs –2.29 (–7.35, 2.87)
–0.25 (–4.73, 4.08) 0.05 (–4.05, 4.18) 2.29 (–2.87, 7.35) Telbivudine
E: MELD score                                 MD (95 % CI)
Enticavir 0.70 (–1.82, 3.39) –3.79 (–10.08, 2.80) 4.08 (0.77, 7.52) –1.16 (–6.07, 4.02)
–0.70 (–3.39, 1.82) Lamivudine –4.47 (–10.93, 2.25) 3.37 (–0.23, 7.07) –1.91 (–6.83, 3.17)
3.79 (–2.80, 10.08) 4.47 (–2.25, 10.93) Tenofovir 7.85 (2.20, 13.27) 2.59 (–5.61, 10.48)
–4.08 (–7.52, –0.77) –3.37 (–7.07, 0.23) –7.85 (–13.27, –2.20) non-NAs –5.24 (–11.11, 0.66)
1.16 (–4.02, 6.07) 1.91 (–3.17, 6.83) –2.59 (–10.48, 5.61) 5.24 (–0.66, 11.11) Telbivudine
F: Mortality                                   OR (95 % CI)
Enticavir 0.91 (0.47, 1.72) 0.39 (0.02, 5.02) 1.46 (0.69, 3.38) 0.95 (0.24, 3.29)
1.10 (0.58, 2.13) Lamivudine 0.43 (0.03, 5.17) 3.91 (1.45, 10.50) 0.59 (0.09, 3.07)
2.54 (0.20, 46.38) 2.34 (0.19, 38.96) Tenofovir 9.14 (0.88, 133.01) 1.34 (0.06, 36.58)
0.69 (0.30, 1.44) 0.26 (0.10, 0.69) 0.11 (0.01, 1.13) non-NAs 0.15 (0.02, 1.06)
1.05 (0.30, 4.17) 1.69 (0.33, 10.60) 0.75 (0.03, 15.74) 6.70 (0.94, 56.52) Telbivudine
CI – confidence interval, MELD – model for end-stage liver disease, non-NAs – non-nucleoside analogues, OR – 
odds risk
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the highest, but there was no significant difference compared to the enticavir group (OR: 
1.09; 95 % CI: 0.05–22.52), lamivudine group (OR: 1.25; 95 % CI: 0.07–27.34), tenofovir group 
(OR: 1.38; 95 % CI: 0.01–204.33) and non-NAs group (OR: 1.32; 95 % CI: 0.13–99.93). The two-
month survival rate (Table III and Fig. 2b) of the tenofovir group was the highest, but the 
differences were not significant compared to the enticavir group (OR: 6.18; 95 % CI: 0.35–
163.02), lamivudine group (OR: 7.77; 95 % CI: 0.43–188.47), telbivudine group (OR: 6.73; 95 
% CI: 0.26–202.01) and non-NAs group (OR: 12.37; 95 % CI: 0.88–248.54). Further, the three-
month survival rate (Table III and Fig. 2c) of the tenofovir group was the highest and the 
difference was significant compared to the non-NAs group (OR: 8.30; 95 % CI: 1.31–69.38). 
However, the differences compared with the other nucleoside analogues, including the 
enticavir group (OR: 3.94; 95 % CI: 0.57–33.21), lamivudine group (OR: 3.09; 95 % CI: 0.46–
25.94) and telbivudine group (OR: 4.18; 95 % CI: 0.51–39.41) were not significant.
Network meta-analysis of HBV DNA
The p < 0.05 suggested that there was significant inconsistency (Table II). The PSRFs 
ranged from 1.00 to 1.03, indicating that model convergences were complete. Hence, an 
inconsistency model was used. Our results from Table III show that the concentration of 
HBV DNA in the enticavir group was the lowest and there was a significant difference 
compared to the non-NAs group (MD = –2.66, 95 % CI: –5.19 to –0.16), but there were no 
significant differences between the enticavir group and the other two nucleoside analogue 
groups, including the lamivudine group (MD: –0.33; 95 % CI: –1.91 to 1.25) and telbivudine 
group (MD: –0.25; 95 % CI: –4.73 to 4.08).
Fig. 2. Rank probability of different treatments: a) one-month survival rate, b) two-month survival rate, 
c) three-month survival rate, d) model for end-stage liver disease (MELD) score. Rank 1 is the best, in-
dicating the highest treatment effect, and rank 5 is the worst, indicating the lowest treatment effect.
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Network meta-analysis of MELD score
Inconsistency assessment for the MELD score revealed that all p-values were greater 
than 0.05 (Table II) and PSRFs ranged from 1.00 to 1.02. Hence, a consistency model was 
chosen. As shown in Table III and Fig. 2d, the tenofovir group had the lowest MELD score. 
There was also a significant difference between the tenofovir group and the non-NAs 
group (MD: –7.85, 95 % CI: –13.27 to –2.20) while the differences between the tenofovir 
group and the other nucleoside analogues groups, including enticavir group (MD: –3.79; 
95 % CI: –10.08 to 2.80), lamivudine group (MD: –4.47; 95 % CI: –10.93 to 2.25) and telbivu-
dine group (MD: –2.59; 95 % CI: –10.48 to 5.61), were not significant.
Network meta-analysis of mortality
p-Values between the lamivudine group and the non-NAs group and between the 
enticavir group and the non-NAs group were found to be less than 0.05 (Table II), indicat-
ing that the inconsistency was significant. The PSRFs ranged from 1.00 to 1.03 and, as a 
result, an inconsistency model was used. Mortality of the tenofovir group was found to be 
the lowest (Table III). However, there were no significant differences compared to the en-
ticavir group (OR: 0.39; 95 % CI: 0.02–5.02), lamivudine group (OR: 0.43; 95 % CI: 0.03–5.17), 
telbivudine group (OR: 0.75; 95 % CI: 0.03–15.74) and non-NAs group (OR: 0.11; 95 % CI: 
0.01–1.13).
DISCUSSION AND LIMITATIONS
It is reported that the three-month survival rate of ACLF patients receiving tenofovir 
treatment was significantly higher than that of the placebo group, and the MELD score and 
HBV DNA level were significantly reduced in the tenofovir group compared to the placebo 
group (22). In addition, tenofovir inhibited the viral DNA replication of lamivudine-resis-
tant HBV in patients infected with HBV or patients co-infected with HBV and HIV (27). 
Besides, Ceylan et al. (28) reported that the virological response was better in chronic HBV 
infected patients treated with tenofovir than in patients treated with entecavir, while the 
side effects were not significantly different between the two nucleoside analogues. Fur-
thermore, Lee et al. (29) revealed that in patients infected with lamivudine-resistant HBV, 
tenofovir monotherapy was as effective as the combination of tenofovir with lamivudine 
or telbivudine. It is also reported that treatments with both tenofovir and telbivudine were 
effective and the safety of the two nucleoside analogues was acceptable, but the estimated 
glomerular filtration rate (eGFR) was deteriorated in the tenofovir group while the telbi-
vudine group showed improvement in eGFR (30). In addition, tenofovir had superior an-
tiviral efficacy in patients with chronic hepatitis B compared to adefovir, another nucleo-
side analogue with a similar safety profile (31). Also, tenofovir was reported to have 
successfully rescued a hepatic decompensation patient infected with an adefovir resistant 
HBV mutant (32). The results of these studies demonstrate that the effects of tenofovir for 
treating HBV infection are better than or as good as other nucleoside analogues, including 
lamivudine, entecavir, telbivudine, tenofovir and adefovir, while their safety is acceptable. 
In line with previous studies, our present study showed that tenofovir treatment had the 
highest two-month and three-month survival rates, indicating that the patients treated 
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with tenofovir had a higher short-term survival rate compared to patients treated with 
other nucleoside analogues despite the differences not being significant. Besides, patients 
treated with tenofovir showed the lowest MELD score and mortality, suggesting that pa-
tients might have a better prognosis after being treated with tenofovir. Such results indi-
cated that tenofovir was more effective than other nucleoside analogues and non-NAs in 
the treatment of patients with HBV-related liver failure.
To the best of our knowledge, this study was the first network meta-analysis compar-
ing the efficacy of four nucleoside analogues, including lamivudine, entecavir, telbivudine 
and tenofovir, and non-NAs treatment, for the treatment of HBV-related liver failure. Ma-
jor limitations of our study were as follows. First, due to incomplete data, no subgroup 
analysis was conducted. Second, not all drugs formed an closed loop and the number of 
included studies was limited, which might have resulted in exaggerated efficacy. Third, 
this study was unable to include all nucleoside analogues such as adefovir because of the 
lack of suitable studies. Fourth, out of 12 included studies, ten were conducted in China, 
and the other 2 studies were also from Asian countries, which might be associated with 
race and treatments. Hence, further tracking of related studies is needed. Fifth, only 2 RCT 
studies were included in the present study, the majority of studies were cohort studies, the 
level of evidence of which was not as good as RCT. Further studies could not be performed 
because of fewer RCT studies. 
CONCLUSIONS
In the present study, to compare the therapeutic effect of four nucleoside analogues, 
we conducted a network meta-analysis based on the Bayesian framework. Our results 
showed that the tenofovir treatment had the highest two-month and three-month sur-
vival rates, the lowest MELD score and mortality. In conclusion, to compare the efficacy of 
NAs in the treatment of HBV-related liver failure, our results suggested that tenofovir 
might be better therapy for the treatment of HBV-related liver failure than other nucleoside 
analogues and non-NAs. The results of our meta-analysis may be useful as a guide for the 
clinical treatment of HBV-related liver failure.
Acronyms. – CI – confidence interval, eGFR – estimated glomerular filtration rate, HBV – hepa-
titis B virus, HIV – immunodeficiency virus, MCMC – Markov chain Monte Carlo, MD – mean dif-
ference, MELD – model for end-stage liver disease, NOS -–Newcastle-Ottawa scale (NOS), non-NAs 
– non-nucleoside analogues, OR – odds risk, PSFR – potential scale reduction factor, RCT – random-
ized controlled trial
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